Injectable Drug Delivery Articles

1. In Vivo's Biggest Threat — Comparison To Old Models 1/23/2026
2. Conducting A Medical Device Stability Study: A Practical Guide 1/7/2026

   Stability studies measure how medical devices respond to environmental stresses such as temperature, humidity, light, and time. Let's take a closer look at designing and conducting a stability study.

3. Nanotechnology Drug Delivery: A Market Overview 1/6/2026

   New market research reveals the scientific, geopolitical, and business trends driving growth in the nanotechnology drug delivery market.

4. Combination: The Drug Delivery Word Of The Year For 2026 12/30/2025

   In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.

5. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

   By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

6. Electronic Drug Delivery Devices Market: Advancing Smart, Connected Healthcare 12/19/2025

   What is factoring into market growth for electronic drug delivery devices and why? New market research shares key insights.

7. Regulating For Patient Safety And Success With Combination Products 12/16/2025

   At the AFDO/RAPS Combination Products Summit 2025, a notable focus emerged around approaches to risk assessment and human factors studies. In this article, Chief Editor Tom von Gunden offers his appreciation for the biopharma industry’s consideration of patient usability and safety in the development and regulation of combination products and other drug delivery devices. 

8. FDA Issues Final Guidance For pH Adjuster Waiver Requests For Generic Drugs 12/11/2025

   The FDA has issued a final guidance, Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use.

9. Is Oncology Precision Medicine Coming of Age? 12/3/2025

   Developers are releasing new data suggesting that their targeted therapy candidates may finally address some of oncology’s toughest challenges.

10. Drug Delivery Trends From 2025: Top 4 For Momentum Gains In 2026 12/2/2025

    In this article, Fran DeGrazio identifies four notable trends in drug delivery that gained momentum in 2025 and, she predicts, will continue to do so in 2026 and beyond. They are digitalization, sustainability, patient centricity, and the advanced delivery of complex biopharmaceuticals.